Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iSpecimen Inc. filings document material events, governance matters, capital-structure changes, and reporting status for the company’s Nasdaq-listed common stock. Recent 8-K disclosures cover the completed 1-for-40 reverse stock split, related certificate amendments, Regulation FD press-release exhibits, shareholder meeting adjournments, and board composition changes.
The company’s regulatory record also includes emerging growth company disclosures and a Rule 12b-25 notice tied to its annual report filing process. These filings provide formal records of iSpecimen’s public-company obligations alongside its biospecimen marketplace operations.
iSpecimen Inc. has been unable to complete its 2025 Annual Meeting of Stockholders because not enough shareholders have participated to reach a quorum. The meeting, originally convened on December 31, 2025 and reconvened on January 23, 2026, February 13, 2026, and March 13, 2026, was adjourned each time for this reason.
The company now plans to reconvene the Annual Meeting on April 10, 2026 at 9:00 a.m. Eastern Time. The record date remains November 3, 2025, and the proposals to be voted on are unchanged from those described in the definitive proxy statement filed on November 21, 2025.
iSpecimen Inc. reported that Siyun Yang resigned from its Board of Directors effective February 17, 2026. The company stated that her resignation was not due to any disagreement regarding operations, policies, or practices.
Ms. Yang had served as an independent director since February 2025 and sat on both the Audit Committee and the Nominating and Corporate Governance Committee. iSpecimen thanked her for her service and expressed well wishes for her future endeavors.
iSpecimen Inc. reported that its 2025 Annual Meeting of Stockholders, originally convened on December 31, 2025, has been repeatedly adjourned because not enough shares were represented to reach a quorum. The meeting was reconvened on January 23, 2026 and February 13, 2026, but a quorum was still not present.
The company now plans to reconvene the Annual Meeting on March 13, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of November 3, 2025 remain entitled to vote, and the proposals to be considered are unchanged from those described in the November 21, 2025 proxy statement.
iSpecimen Inc. filed a current report to share two operational updates. The company has completed Milestone 2 of its SalesStack digital transformation program, delivering a fully integrated, live production marketplace that connects customer requests with supplier inventories and supports core workflows like order processing and user management.
The new marketplace is live at mp.ispecimen.com and is designed to streamline operations, reduce costs, and support future growth through AI-assisted matching and legacy system sunset. Separately, iSpecimen highlighted recent performance of its site network, including rapidly procuring 500 influenza swab samples in a few weeks and consistently supplying cerebrospinal fluid for ongoing customer studies, alongside strong customer feedback on specimen quality and documentation.
iSpecimen Inc. filed a current report to share two operational updates. The company has completed Milestone 2 of its SalesStack digital transformation program, delivering a fully integrated, live production marketplace that connects customer requests with supplier inventories and supports core workflows like order processing and user management.
The new marketplace is live at mp.ispecimen.com and is designed to streamline operations, reduce costs, and support future growth through AI-assisted matching and legacy system sunset. Separately, iSpecimen highlighted recent performance of its site network, including rapidly procuring 500 influenza swab samples in a few weeks and consistently supplying cerebrospinal fluid for ongoing customer studies, alongside strong customer feedback on specimen quality and documentation.
iSpecimen Inc. is registering up to 101,000,000 shares of common stock for resale by existing investors. These shares are issuable upon conversion of Series C Convertible Non-Voting Preferred Stock that was sold in a December 2025 private placement for approximately $5.5 million of gross proceeds.
The company will not receive any proceeds from sales of these shares by the selling stockholders. After full conversion and completion of this offering, iSpecimen states there would be 110,771,046 shares of common stock outstanding. Its stock trades on the Nasdaq Capital Market under the symbol ISPC, and the company recently regained compliance with Nasdaq’s stockholders’ equity rules but remains below the $1.00 minimum bid requirement.
iSpecimen Inc. is experiencing delays in completing its 2025 Annual Meeting of Stockholders due to repeated failure to reach a quorum. The company first convened the meeting on December 31, 2025, but adjourned it when too few shares were represented to conduct official business.
The meeting was reconvened on January 23, 2026 and again adjourned for the same quorum issue to give stockholders more time to vote on the proposals outlined in the definitive proxy statement filed on November 21, 2025. iSpecimen now intends to reconvene the Annual Meeting on February 13, 2026, keeping the record date of November 3, 2025 unchanged, meaning only holders of record on that date are entitled to vote.
iSpecimen Inc. is registering 101,000,000 shares of common stock for resale by investors who hold Series C Convertible Non-Voting Preferred Stock issued in a December 2025 private placement. These “Conversion Shares” will become issuable upon conversion of 6,875 Series C preferred shares and any related anti-dilution adjustments under the Certificate of Designation. After the offering, iSpecimen would have 110,771,046 common shares outstanding if all Conversion Shares are issued.
The company will not receive proceeds from sales by the selling stockholders. It already raised approximately $5.5 million in gross proceeds in the December 2025 private placement, paying a 4% cash commission to E.F. Hutton & Co. and using $2,000,000 for marketing and investor relations services from IR Agency LLC, with the remainder for working capital and general corporate purposes. iSpecimen notes that large resales under this registration could put downward pressure on its share price.
iSpecimen operates an online biospecimen marketplace connecting healthcare providers with life science researchers. The company recently regained compliance with Nasdaq’s stockholders’ equity rules but remains out of compliance with the $1.00 minimum bid price requirement and has until May 18, 2026 to cure this deficiency. Its common stock trades on the Nasdaq Capital Market under the symbol “ISPC”.
iSpecimen Inc. filed an amended current report to update the terms of its Series C Convertible Non-Voting Preferred Stock. On January 16, 2026, the company filed an Amended Certificate of Designation that modifies Section 7 of the original designation. The change makes both the Conversion Price and the Floor Price subject to proportionate adjustment if there is any reverse stock split, share combination or similar transaction that reduces the number of outstanding common shares.
The amendment was approved by the company and holders of more than a majority of the outstanding Series C Preferred Stock, as permitted under the original terms. All other rights, preferences and privileges of the Series C Preferred Stock remain unchanged.